Identification of myeloid derived cells which regulates ovarian cancer dissemination
Project/Area Number |
24791702
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Obstetrics and gynecology
|
Research Institution | Osaka University |
Principal Investigator |
ISOBE Aki 大阪大学, 医学(系)研究科(研究院), 助教 (60397619)
|
Project Period (FY) |
2012-04-01 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 骨髄由来細胞 / M2マクロファージ / IL-6 / 腹膜播種 / M2マクロファージ / IL-6 / 卵巣癌腹膜播種 |
Research Abstract |
From ovarian cancer ascites, we found CD11b+CD14+ cells expressed significantly high levels of IL-6 compared with other populations of cells and FACS analyses revealed about 88% of CD11b+CD14+ were mannose receptor, CD206 positive, indicating these populations of cells are predominantly M2-polarized macrophages, TAMs. When CD11b+CD14+ cells were co-cultured with ovarian cancer cells, the invasion as well as the proliferation of cancer cells were so promoted and these promotions were almost completely inhibited by the pretreatment with anti-IL-6R antibody, while anti-IL-6R antibody did not affect ovarian cancer cell invasion and proliferation without CD11b+CD14+ cells, indicating TAMs enhance ovarian cancer proliferation or invasion by secreting a certain amount of IL-6. M2-polarized macrophages present in ovarian cancer ascites play a crucial role in ovarian cancer progression by secreting IL-6. Targeting IL-6/IL-6R signaling has a therapeutic potential for ovarian cancer treatment.
|
Report
(3 results)
Research Products
(5 results)